ArticleEuropean urology2010
Words of wisdom. Re: Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Maxeiner A, Adkins CB, Zhang Y, et al. Prostate 2010;70:710-7.
Article in European urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Article
- Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.British journal of cancer · 2017Article
- A decade in prostate cancer: from NMR to metabolomics.Nature reviews. Urology · 2011Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The authors analysed the value of metabolomic profiles to predict biochemical progression (BP) risk in patients with prostate cancer (PCa) submitted to radical prostatectomy(RP). They retrospectively analysed 183 PCa cases submitted to RP, using an intact-tissue magnetic resonance spectroscopy(MRS) method. A high-resolution, magic-angle, spinning proton MRS was used to investigate a metabolomic analysis of still-intact prostate tissue. This method allows study of chemical metabolites in their native state and control of intact tissue spectra, preserving the tissue for pathologic analysis. In this study, metabolomic profiles analysed by MRS could differentiate cases of PCa with BP after RP from clinical and pathologic-stage matched cases without BP.The major contributing factors to the observed metabolomic profiles were changes in spermine polyamines,phosphoryl choline, glutamine, inositol, and glutamate. The overall accuracy for predicting BP based on metabolomic profiles ranged from 71% to 78%. The suggestion is that PCa metabolic profiles studied at RP with MRS may provide available adjunct parameter to predict the risk of progression after surgery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.